Tandem Diabetes Care | TNDM - Cost Of Sales


Tandem Diabetes Care reported $122.92M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 5.3B 380M Mar/2026
Accuray USD 116.17M 14.63M Dec/2024
Align Technology USD 363.97M 7.48M Dec/2025
AtriCure USD 35.16M 2.23M Dec/2025
Baxter International USD 2.4B 512M Dec/2025
Becton, Dickinson and Co. USD 2.84B 2.35B Dec/2025
Boston Scientific USD 1.83B 8M Mar/2026
Cooper Companies USD 376.8M 87.4M Dec/2025
Dexcom USD 466.9M 11M Dec/2025
Edwards Lifesciences USD 362.6M 19.6M Mar/2026
Eli Lilly USD 3.37B 363.7M Dec/2025
Globus Medical USD 290.47M 8.09M Dec/2025
ICU Medical USD 337.72M 1.61M Dec/2025
Inogen USD 39.59M 1.27M Sep/2024
Insulet USD 215.2M 19M Dec/2025
Integra LifeSciences USD 193.44M 1.62M Dec/2025
Intuitive Surgical USD 940.3M 21.6M Mar/2026
J&J USD 8.07B 103M Mar/2026
Masimo USD 165.2M 24.3M Dec/2025
Medtronic USD 3.61B 83M Dec/2025
Merit Medical Systems USD 198.58M 838K Dec/2025
Orthofix International USD 66.63M 6.4M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Stryker USD 2.69B 373M Dec/2025
Tandem Diabetes Care USD 122.92M 7.96M Dec/2025
Teleflex USD 261.54M 199.84M Dec/2025
Zimmer Biomet Holdings USD 970.1M 234.3M Dec/2025